# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Word to the wise: Ed Yardeni, in a July 4 note, warns his clients: "Too much capital can end even the best of parties."
Moderna announced a $176 million award for the development of an mRNA-based Influenza vaccine.
The medical and pharmaceutical community continues to embrace emerging technologies, beginning with mRNA that rose to fame duri...
Pfizer and Moderna continue their legal battle over COVID-19 vaccine patents following a mixed ruling by London's High Cour...
- Reuters
- Reuters
The funds will be utilized to finalize the late-stage development and testing of a pre-pandemic mRNA-based vaccine against H5N1...